A Phase 1/2A, Multicenter, Open-Label, First In Human Study To Assess The Safety, Tolerability, Pharmacokinetics, And Preliminary Antitumor Activity Of Db-1311 In Subjects With Advanced/Metastatic Solid Tumors
Posted Date: Apr 26, 2024
- Investigator: Trisha Wise-Draper
- Specialties:
- Type of Study: Drug
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311 in subjects with advanced solid tumors.
Criteria:
Null
Keywords:
Advanced Solid Tumors
For More Information:
Kayla Webb
NULL
cancer@uchealth.com